In our ongoing exploration of treatment options for suppressing tics, we’ve discussed numerous approaches, such as medications and behavioral therapies like Habit Reversal Training (HRT). While these strategies can be effective for some children and teens, results can vary significantly.
Parents of children with Tourette Syndrome understandably yearn for a breakthrough — a definitive, safe treatment that can alleviate their child’s symptoms. In light of this, let’s explore two therapies showing great promise in the realm of Tourette Syndrome treatment: Neopulse and Ecopipam.
Developed by Neurotherapeutics Ltd, a UK-based company focusing on neurological disorders, Neopulse aims to provide a non-drug treatment for tic disorder. The company’s research direction has been heavily influenced by the feedback they’ve received from individuals with tic disorders and their families, who have expressed the need for a safe, effective, and manageable therapy.
Neopulse’s research findings suggest that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist can boost the power and synchronicity of the brain oscillations associated with suppressing movements. This method has shown to substantially reduce the frequency of tics and eliminate the urge-to-tic in individuals with tic disorders.
Currently, they’re testing a wearable wrist device that provides median nerve stimulation at the push of a button, aiming to give individuals control over their tics. Alongside this device, Neopulse is also developing an app to track Tourette Syndrome symptoms over time and analyze any external factors that may influence them.
For more information, visit: Neopulse Website
Ecopipam, an investigational drug developed by US-based Emalex Biosciences, is showing potential for the treatment of Tourette Syndrome. Emalex’s focus is on treatments for central nervous system disorders.
Most current, approved medications for Tourette Syndrome are antipsychotics, which are limited due to risks of weight gain, metabolic changes, and drug-induced movement disorders. Ecopipam, as a selective dopamine 1 receptor antagonist, is now in Phase 3 clinical trials. The drug has shown good tolerability in clinical trials so far and has earned both Orphan Drug and Fast Track designation from the FDA for the treatment of Tourette Syndrome.
Several small trials in children aged 6-18 suggest that Ecopipam is well-tolerated and effective at reducing tics, with a lower risk of the side effects commonly seen with earlier drugs. The results indicate a significant reduction in tic scores in the Ecopipam group compared with the placebo group.
Both Neopulse and Ecopipam represent exciting advancements in the field of Tourette Syndrome treatment. It’s crucial to remember, however, that these treatments are still in the development and testing stages. We remain hopeful that these treatments will pave the way for better, more efficient solutions for individuals living with Tourette Syndrome.